Alimera Sciences (NASDAQ: ALIM) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it compare to its rivals? We will compare Alimera Sciences to related companies based on the strength of its risk, earnings, profitability, institutional ownership, analyst recommendations, valuation and dividends.
Institutional & Insider Ownership
37.2% of Alimera Sciences shares are owned by institutional investors. Comparatively, 45.2% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.7% of Alimera Sciences shares are owned by company insiders. Comparatively, 14.9% of shares of all “Biopharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Alimera Sciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Alimera Sciences Competitors||-13,404.97%||246.04%||-20.09%|
This is a breakdown of recent recommendations and price targets for Alimera Sciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Alimera Sciences Competitors||117||754||1615||58||2.63|
Alimera Sciences presently has a consensus target price of $4.00, indicating a potential upside of 181.69%. As a group, “Biopharmaceuticals” companies have a potential upside of 6.49%. Given Alimera Sciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Alimera Sciences is more favorable than its rivals.
Valuation and Earnings
This table compares Alimera Sciences and its rivals gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Alimera Sciences||$35.96 million||-$16.78 million||-3.64|
|Alimera Sciences Competitors||$579.30 million||$241.72 million||-6.59|
Alimera Sciences’ rivals have higher revenue and earnings than Alimera Sciences. Alimera Sciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility & Risk
Alimera Sciences has a beta of 2.2, indicating that its stock price is 120% more volatile than the S&P 500. Comparatively, Alimera Sciences’ rivals have a beta of 1.28, indicating that their average stock price is 28% more volatile than the S&P 500.
Alimera Sciences rivals beat Alimera Sciences on 7 of the 12 factors compared.
Alimera Sciences Company Profile
Alimera Sciences, Inc. (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina. The Company’s product is ILUVIEN, which is developed to treat diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. In the United States, ILUVIEN is indicated for the treatment of DME in patients who have been treated with a course of corticosteroids and did not have a rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries, ILUVIEN is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.